Aerie Pharmaceuticals, Inc. Announces Study Results Supporting Additional Mechanism Of Action For Lead Glaucoma Drug Candidate AR-13324
Published: Feb 25, 2014
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the results of preclinical in vivo research demonstrating the ability of AR-13324 to reduce episcleral venous pressure (EVP) in the eye.
Help employers find you! Check out all the jobs and post your resume.